Anti-Human NECTIN4 Antibody (P1E7)

Catalog No.

RHJ41001

Species reactivity

Human

Host species

Human

Isotype

IgG1, lambda

Clonality

Monoclonal

Applications

ELISA, WB

Target

LNIR, NECTIN4, PRR4 receptor-related protein 4, Nectin cell adhesion molecule 4, Ig superfamily receptor LNIR, Nectin-4, PVRL4

Concentration

2.47 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q96NY8

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

P1E7

Note

For research use only.

Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer., PMID:39513959

Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China., PMID:39530574

Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects., PMID:39577073

Assessing the expression of Nectin-4 in solid tumors by immunohistochemistry - what do we know?, PMID:39582282

Lung Toxicity Occurring During Enfortumab Vedotin Treatment: From a Priming Case Report to a Retrospective Analysis., PMID:39598456

[Muscle-invasive and metastatic urothelial carcinoma from a pathological point of view]., PMID:39603252

Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review., PMID:39626158

[Pathology and molecular pathology of carcinoma of the penis]., PMID:39694900

Nectin-4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study., PMID:39748460

Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis., PMID:39754977

NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA., PMID:39763905

Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives., PMID:39764422

Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer., PMID:39801278

Antibody-drug conjugates in urothelial carcinoma: current status and future., PMID:39844537

Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions., PMID:39858014

Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma., PMID:39877564

Tissue-Based Biomarkers Important for Prognostication and Management of Genitourinary Tumors, Including Surrogate Markers of Genomic Alterations., PMID:39890303

Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium., PMID:39890750

Durable response to treatment of an atypical desmoplastic small round cell tumor with enfortumab-vedotin., PMID:39928161

Nectin-4: A promising prognostic marker and therapeutic target in cancer., PMID:39939077

225Ac/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer., PMID:39978811

Understanding the Toxicity Profile of Approved ADCs., PMID:40006625

A novel and promising therapeutic approach for treating pancreatic cancer: Nectin‑4‑targeted antibody‑drug conjugates alone or combined with autophagy inhibitors., PMID:40017149

Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies., PMID:40046734

Spatial Expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and Metastases: Implications for Pathological and Clinical Management., PMID:40086591

Theranostic implications of Nectin-4 oncoprotein in gynecologic cancers: A review., PMID:40101551

Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer., PMID:40129250

A case of remarkable response to combined radiation therapy, enfortumab vedotin, and pembrolizumab in metastatic urothelial carcinoma., PMID:40160871

Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers., PMID:40187750

Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas., PMID:40198857

Nectin-4 expression patterns and therapeutics in oncology., PMID:40209851

High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy., PMID:40215164

Strategies to overcome resistance to enfortumab vedotin and pembrolizumab for patients with urothelial carcinoma: harnessing present knowledge for future advances., PMID:40225697

Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report., PMID:40235861

Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer., PMID:40252843

9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase Ⅰ/Ⅱ study., PMID:40288679

Biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and the immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma., PMID:40327767

Immune Checkpoint Inhibitors and Antibody-Drug Conjugates in Urothelial Carcinoma: Current Landscape and Future Directions., PMID:40361519

Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4., PMID:40380880

NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors., PMID:40392373

Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer., PMID:40401457

Trop2, Nectin-4, and PD-L1 expression profiles in esophageal squamous cell carcinoma: Implications for combined immunotherapy and ADC targeted therapies., PMID:40403357

Assessment of trophoblast cell-surface antigen 2 (TROP2) and nectin-4 expression in choriocarcinoma., PMID:40414312

E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale., PMID:40421891

Ecology and evolutionary trajectories of morbilliviruses in Neotropical bats., PMID:40425830

Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions., PMID:40433388

Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer., PMID:40474033

Enfortumab vedotin induced interstitial lung disease: A first case report with pathological evidence from transbronchial lung cryobiopsy., PMID:40496844

Mechanistic Insights into Anti-Nectin4-VcMMAE-Induced Ocular Toxicity: From Cellular Uptake Pathways to Molecular Modification., PMID:40507807

The antibody-drug conjugate sacituzumab govitecan (IMMU-132) represents a potential novel therapeutic strategy in cholangiocarcinoma., PMID:40509933

Document Download

Anti-Human NECTIN4 Antibody (P1E7).pdf